

Amendments to the Claims:

Please amend claims 40, 46-47, 49-51 and 53-54 and cancel claims 39, 52 and 55 as follows. This listing of claims will replace all prior versions and listings of claims in this application:

Listing of Claims:

1-39. (Canceled).

40. (Currently Amended) ~~[[The]]~~ An isolated antibody or antigen-binding fragment thereof ~~according to claim 39 that~~ specifically binds to pleiotrophin (PTN) comprising any one of the following:

(a) a monoclonal antibody or antigen-binding fragment thereof produced by ~~[[a]]~~ the hybridoma cell line ~~selected from the group consisting of 3B10, 4B2, 10, 17, 24, 25, 26, 27, 31, 41, 50, 60, 87, 3-4A, and 3-11F;~~

(b) an antibody or antigen-binding fragment thereof that binds to an epitope, which is ~~substantially~~ the same as an epitope of the monoclonal antibody or antigen-binding fragment thereof produced by ~~[[a]]~~ the hybridoma cell line ~~selected from the group consisting of 3B10, 4B2, 10, 17, 24, 25, 26, 27, 31, 41, 50, 60, 87, 3-4A, and 3-11FA;~~ or

(c) an antibody that competitively inhibits binding of a PTN polypeptide to an antibody ~~comprising a sequence comprising SEQ ID NOs: 5, 6, 7, 10, 11, and 12, or SEQ ID NOs: 3 and 8,~~ ~~wherein the antibody or antigen-binding fragment comprises:~~ (i) a light chain CDR1 sequence of SEQ ID NO:10, (ii) a light chain CDR2 sequence of SEQ ID NO:11, (iii) a light chain CDR3 sequence of SEQ ID NO:12, (iv) a heavy chain CDR1 sequence of SEQ ID NO:5, (v) a heavy chain CDR2 sequence of SEQ ID NO:6 and (vi) a heavy chain CDR3 sequence of SEQ ID NO:7.

41-45. (Canceled).

46. (Currently Amended) The antibody or antigen-binding fragment thereof according to claim 40~~[[39]]~~, ~~wherein said antibody comprises an amino acid sequence comprising sequences with at~~

~~least about 90% sequence identity with SEQ ID NOs: 5, 6, 7, 10, 11, and 12, or SEQ ID NOs: 3 and 8;~~

wherein the antibody or antigen-binding fragment comprises: (i) a light chain CDR1 sequence of SEQ ID NO:10, (ii) a light chain CDR2 sequence of SEQ ID NO:11, (iii) a light chain CDR3 sequence of SEQ ID NO:12, (iv) a heavy chain CDR1 sequence of SEQ ID NO:5, (v) a heavy chain CDR2 sequence of SEQ ID NO:6 and (vi) a heavy chain CDR3 sequence of SEQ ID NO:7.

47. (Currently Amended) The antibody or antigen-binding fragment thereof according to claim 46[[39]], wherein said antibody comprises a[[n]] heavy chain variable domain amino acid sequence comprising SEQ ID NOs: 3 and a light chain variable domain amino acid sequence comprising SEQ ID NOs: 8;

~~wherein the antibody or antigen-binding fragment comprises: (i) a light chain CDR1, (ii) a light chain CDR2, (iii) a light chain CDR3, (iv) a heavy chain CDR1, (v) a heavy chain CDR2, and (vi) a heavy chain CDR3.~~

48. (Canceled).

49. (Currently Amended) The antibody or antigen-binding fragment thereof according to claim 40[[39]], wherein said antibody is selected from the group consisting of a chimeric antibody, humanized antibody, and a fully human antibody.

50. (Currently Amended) The antibody or antigen-binding fragment thereof according to claim 40[[39]], wherein said antigen-binding fragment is selected from the group consisting of Fab fragment, (Fab')₂ Fragment, and a Fv fragment.

51. (Currently Amended) The antibody or antigen-binding fragment thereof of claim 40[[39]], wherein the antibody is conjugated to a cytotoxic agent.

52. (Canceled).

53. (Currently Amended) The antibody or antigen-binding fragment thereof according to claim 40[[39]], wherein said antibody binds to a PTN epitope at a binding affinity of at least 10^6M^{-1} .

54. (Currently Amended) A pharmaceutical composition comprising the antibody according to claim 40[[39]] and a pharmaceutical carrier.

55. (Canceled).